GSC
TSHA icon

Ground Swell Capital’s Taysha Gene Therapies TSHA Stock Holding History

Ground Swell Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,660
Closed -$25.4K – 260
2024
Q4 		$25.4K Buy
+14,660
New +$30.4K 0.04% 110

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ground Swell Capital's TSHA Position: Q1 2025 in Review

Ground Swell Capital sold out of Taysha Gene Therapies (TSHA) in Q1 2025, closing a stake of 14,660 shares — an estimated $25.4K sold.

Ground Swell Capital first reported a position in TSHA in Q4 2024 and held it in 1 quarter. The position peaked at $25.4K in Q4 2024. 127 funds tracked by Wall St. Rank hold TSHA as of Q1 2025.

  • Ground Swell Capital reported no remaining Taysha Gene Therapies position as of Q1 2025 after selling out during the quarter.
  • Ground Swell Capital sold 14,660 Taysha Gene Therapies shares in Q1 2025, an estimated $25.4K.
  • Ground Swell Capital first reported a position in Taysha Gene Therapies in Q4 2024 and held it in 1 quarter.
  • Ground Swell Capital's Taysha Gene Therapies position peaked at $25.4K in Q4 2024.
  • 127 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2025.

Based on Ground Swell Capital's 13F filing for Q1 2025, filed 13 May 2025.